Ranibizumab in diabetic macular edema

查看全文 作　　者：Claudia [1]Krispel;Murilo [1]Rodrigues;Xiaoban [1]Xin;Akrit [1]Sodhi

机构地区：[1]Wilmer Eye Institute,Johns Hopkins School of Medicine,Baltimore,MD 21287,United States

出　　处：《World Journal of Diabetes》索引2013年第4卷第6期,共9页

基　　金：Supported by National Eye Institute,National Institutes of Health Grant,No.K08-EY021189;an Unrestricted Grant from Research to Prevent Blindness;A Career Development Award Recipient from the Research to Prevent Blindness Foundation to Dr.Sodhiand;Scholar at the Wilmer Eye Institute to Ryan SJ 摘　　要：By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis). 关键词：Diabetes MACULAR EDEMA Vascular endothelial growth factor RANIBIZUMAB LUCENTIS Bevacizumab AVASTIN INTRAVITREAL injection

相关文献

参考文献（32）
引证文献（3）
耦合文献（19）

参考文献(32)

引证文献(3)

耦合文献(19)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Ranibizumab in diabetic macular edema

参考文献(32)

引证文献(3)

耦合文献(19)

用户提示